BILL NUMBER: AB 1330 INTRODUCED BILL TEXT INTRODUCED BY Assembly Member Evans FEBRUARY 23, 2007 An act to add Section 16519 to the Welfare and Institutions Code, relating to child welfare. LEGISLATIVE COUNSEL'S DIGEST AB 1330, as introduced, Evans. Foster children: psychotropic drugs: data. Existing law provides for oversight by various state and local entities of certain populations of children, including those who are dependent children or wards of the juvenile court, and those who are in foster care, or are otherwise under the supervision of county welfare departments. Existing law provides for a system of child welfare services administered by each county, with oversight by the State Department of Social Services. This bill would require the State Department of Social Services to collect and maintain specified information regarding foster youth who are prescribed psychotropic medication, and to monitor whether those youth receive appropriate medical care and supervision before and after the prescription of the psychotropic medication, in accordance with the recommendations made for the medication by the federal Food and Drug Administration. Vote: majority. Appropriation: no. Fiscal committee: yes. State-mandated local program: no. THE PEOPLE OF THE STATE OF CALIFORNIA DO ENACT AS FOLLOWS: SECTION 1. Section 16519 is added to the Welfare and Institutions Code, to read: 16519. (a) The State Department of Social Services shall collect and maintain the following information regarding each foster youth who is prescribed a psychotropic medication, as defined in subdivision (d) of Section 369.5: (1) The youth's sex, age, and ethnicity or race. (2) The number of years the youth has been in the foster care system. (3) The type of placement within the system, such as foster family, group home, or juvenile justice system. (4) The type of drug prescribed. (b) The department shall monitor whether each youth for whom information is collected pursuant to subdivision (a) receives appropriate medical care and supervision before and after the prescription of the psychotropic medication, in accordance with the recommendations made for the medication by the federal Food and Drug Administration.